http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Oncologic outcomes of squamous cell carcinoma of the anal canal after chemoradiation therapy
Dae Ro Lim(임대로),Hyuk Hur(허혁),Byung Soh Min(민병소),Seung Hyuk Baik(백승혁),Kang Young Lee(이강영),Nam Kyu Kim(김남규) 대한종양외과학회 2016 Korean Journal of Clinical Oncology Vol.12 No.1
Purpose: The aim of this study is to analyze the oncological outcomes of squamous cell carcinoma (SCC) of the anal canal after chemoradiation therapy (CRT) in a single institution. Methods: Fifty-one patients with anal SCC who had been treated with CRT between January 2000 and December 2010 were analyze data single center in Korea. Results: Forty-eight patients exhibited clinical complete response. After a median follow-up of 42.1 months, 13 patients (25.5%) showed recurrence. The disease-free survival (DFS) rate was 63.4% at 5 and 10 years. The overall survival (OS) rates were 83.6% (5 years) and 75.2% (10 years). Stage I: DFS, 100%; OS, 100%; stage II: DFS, 85.7%; OS, 100%; stage IIIA: DFS, 68.6%; OS, 87.5%; stage IIIB: DFS, 34.7%; OS, 48.4%; and stage IV: DFS and OS, 0%. The local recurrence patterns were as follows: pelvic node (n=4, 7.8%), inguinal node (n=1, 2.0%), and inguinal and pelvic node (n=1, 2.0%). The systemic recurrence patterns were as follows: lung (n=2, 3.9%), para-aortic node (n=1, 2.0%), and extrapelvic site (n=2, 3.9%). N-stage represented a single independent prognostic factor for recurrence (P<0.05). Conclusion: CRT for SCC of the anal canal is effective for oncological outcomes and sphincter preservation. The initial nodal status may affect the oncological outcome.
직장에 발생한 위장관 간질성 종양의 외과적 치료 : 단일 기관의 경험
김주흥(Joo Heung Kim),김창희(Chang Hee Kim),허혁(Hyuk Hur),민병소(Byung Soh Min),백승혁(Seung Hyuk Baik),이강영(Kang Young Lee),김남규(Nam Kyu Kim) 대한종양외과학회 2012 Korean Journal of Clinical Oncology Vol.8 No.2
Background : Rectal gastrointestinal tumor is not usually found in rectum and form 0.3% of all rectal malignancy. The aim of this study is to analyze patients who underwent surgical resection for rectal GIST. Methods : We retrospectively reviewed 10 patients who had been underwent curative operation for rectal GIST from 2006 to 2012. Patients were diagnosed with GIST by Abdomino-pelvic CT scan, MRI, or endoscopic ultrasound. Results were analyzed to identify patients characteristics, method and complication of operation, pathologic feature, hospital day, follow-up including neoadjuvent and adjuvant imatinib mesylate (IM). Results : Male and female patients were six and four. The mean age was 62 years (range, 49~81 years) The median follow-up period was 24 month(range, 1~68 months). Except routine checkups, most common chief complaints were constipation (30%). All patients underwent R0 resection (trans-anal surgery (n=2), minimally invasive surgery (n=5), open surgery(n=3)). One laparoscopic operation case was converted to laparotomy due to severe tumor adhesion. The mean size of tumor was 5.4cm (range, 1~8cm). The mitotic count shown >5 in 50 high power fields(HPF) was four cases, near total necrosis was two cases and that shown <5 in HPF was three cases. Five (50%) patients received neoadjuvant imatinib therapy following surgery. Adjuvant imatinib therapy was given to four patients based on size and mitotic counts. One local recurrence cases was found at 4 year 2 month after surgery. Conclusion : We can conclude that curative resection of rectal GIST with imatinib given to neoadjuvant and adjuvant setting is safe. And there are many various surgical options at rectal GIST management, and another study with more cases and logn term follow-up data is indispensable.